(Total Views: 517)
Posted On: 02/15/2021 2:28:59 PM
Post# of 148982
Re: craigakess #78010
CYDY commercial success in non-covid diseases may be much closer than would normally be expected.
For example, if CYDY wants to run a cancer trial, it takes years to complete.
But if CYDY treats one million covid patients, i bet they at least 25,000 of them will be cancer patients.
Leronlimab EUA for covid is one of the largest human cancer trials ever conducted.
Of course EUA for covid is not actually a cancer trial.
What is the regulatory impact of treating 25,000 cancer patients with your drug?
Do you at least get credit for safety?
Surely there is a precedent for a drug which treated a widespread disease and as aresult collected some other indications by virtue of treating humdreds of thousands of patients?
For example, if CYDY wants to run a cancer trial, it takes years to complete.
But if CYDY treats one million covid patients, i bet they at least 25,000 of them will be cancer patients.
Leronlimab EUA for covid is one of the largest human cancer trials ever conducted.
Of course EUA for covid is not actually a cancer trial.
What is the regulatory impact of treating 25,000 cancer patients with your drug?
Do you at least get credit for safety?
Surely there is a precedent for a drug which treated a widespread disease and as aresult collected some other indications by virtue of treating humdreds of thousands of patients?
(1)
(0)Scroll down for more posts ▼
